However, a newly proposed SCLC subtype “SCLC-I,” which is characterized by high expression of immune checkpoints or human leukocyte antigens (HLAs), has been noted to be correlated with cisplatin resistance and shows improved benefits from treatment using chemotherapy combined with immunotherapy (Gay et al., 2021). The gene discussed is HLA-S; the disease is small cell lung carcinoma.